Access to Medicines, Care, and Services for Multiple Sclerosis
Patients in Central and Eastern European Countries: A
Comparative Analysis

a 2023

Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis

SEITARIDOU, Y., M.S. PAVELIU, P. HOLKO, Dominik GREGA, I. TADIC et. al.

Basic information

Original name

Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis

Authors

SEITARIDOU, Y., M.S. PAVELIU, P. HOLKO, Dominik GREGA, I. TADIC, I STEVIC, A. MÄNNIK, T. CHAMOVA, G. PETROVA and M. KAMUSHEVA

Edition

ISPOR Europe 2023, 2023

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

50202 Applied Economics, Econometrics

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.500 in 2022

Organization unit

Faculty of Pharmacy

ISSN

DOI

http://dx.doi.org/10.1016/j.jval.2023.09.1664

Keywords in English

Multiple sclerosis, CEECs, DMTs

Abstract

V originále

Objectives To compare the access of patients with multiple sclerosis (MS) to disease-modifying treatments (DMTs), care, and services in Central and Eastern European countries (CEECs). Methods A 2-part questionnaire-based survey was conducted among experts from six CEECs – Bulgaria, Estonia, Poland, Romania, Serbia, and Slovakia over 4 months (01.12.2022 – 01.04.2023). The first part included questions about access to DMTs – legal requirements about reimbursement and pricing, availability of national pharmacotherapeutic and Health Technology Assessment guidelines, reimbursed DMTs, expenditures for three years (2019 – 2021) from the National Health Insurance Funds (NHIFs) perspectives. The second part included questions about MS patients’ physical and financial access to other services and support. Results Markov modeling is acceptable in Bulgaria, Poland, Slovakia and Serbia, while meta-analysеs of conducted clinical trials are requested in Bulgaria and Poland. In 2019 - 2021, DMTs’ costs increаsed over time, with the highest MS expenditures observed in Poland (€1.15 billion in 2021). All countries provide access to different services and support for MS patients depending on patients disability level. Romania, Estonia, and Serbia ensure complete inpatient care, physiotherapy, and rehabilitation for MS patients. In all CEECs included in the study, the available DMTs were fully reimbursed, and NHIFs completely covered all diagnostic tests and procedures. Assessed by the number of authorized DMTs included in their Positive Drugs Lists, the best access to MS therapy have Bulgaria (84,21%), Poland (78,95%), and Slovakia (78,95%). Conclusions The study revealed differences in MS patients access to DMTs, care, and services amongst included countries. Improving access to MS therapy needs an evaluation of the long-term impact of the barriers as well as frequent feedback from MS patients and stakeholders.

Citovat

SEITARIDOU, Y., M.S. PAVELIU, P. HOLKO, Dominik GREGA, I. TADIC, I STEVIC, A. MÄNNIK, T. CHAMOVA, G. PETROVA and M. KAMUSHEVA. Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis. In ISPOR Europe 2023. 2023. ISSN 1098-3015. Available from: https://dx.doi.org/10.1016/j.jval.2023.09.1664.

@proceedings{2377678,
   author = {Seitaridou, Y. and Paveliu, M.S. and Holko, P. and Grega, Dominik and Tadic, I. and Stevic, I and Männik, A. and Chamova, T. and Petrova, G. and Kamusheva, M.},
   booktitle = {ISPOR Europe 2023},
   doi = {http://dx.doi.org/10.1016/j.jval.2023.09.1664},
   keywords = {Multiple sclerosis, CEECs, DMTs},
   language = {eng},
   title = {Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis},
   url = {https://www.valueinhealthjournal.com/article/S1098-3015(23)04794-0/abstract?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301523047940%3Fshowall%3Dtrue},
   year = {2023}
}

TY  - CONF
ID  - 2377678
AU  - Seitaridou, Y. - Paveliu, M.S. - Holko, P. - Grega, Dominik - Tadic, I. - Stevic, I - Männik, A. - Chamova, T. - Petrova, G. - Kamusheva, M.
PY  - 2023
TI  - Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis
KW  - Multiple sclerosis, CEECs, DMTs
UR  - https://www.valueinhealthjournal.com/article/S1098-3015(23)04794-0/abstract?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301523047940%3Fshowall%3Dtrue
N2  - Objectives To compare the access of patients with multiple sclerosis (MS) to disease-modifying treatments (DMTs), care, and services in Central and Eastern European countries (CEECs). Methods A 2-part questionnaire-based survey was conducted among experts from six CEECs – Bulgaria, Estonia, Poland, Romania, Serbia, and Slovakia over 4 months (01.12.2022 – 01.04.2023). The first part included questions about access to DMTs – legal requirements about reimbursement and pricing, availability of national pharmacotherapeutic and Health Technology Assessment guidelines, reimbursed DMTs, expenditures for three years (2019 – 2021) from the National Health Insurance Funds (NHIFs) perspectives. The second part included questions about MS patients’ physical and financial access to other services and support. Results Markov modeling is acceptable in Bulgaria, Poland, Slovakia and Serbia, while meta-analysеs of conducted clinical trials are requested in Bulgaria and Poland. In 2019 - 2021, DMTs’ costs increаsed over time, with the highest MS expenditures observed in Poland (€1.15 billion in 2021). All countries provide access to different services and support for MS patients depending on patients disability level. Romania, Estonia, and Serbia ensure complete inpatient care, physiotherapy, and rehabilitation for MS patients. In all CEECs included in the study, the available DMTs were fully reimbursed, and NHIFs completely covered all diagnostic tests and procedures. Assessed by the number of authorized DMTs included in their Positive Drugs Lists, the best access to MS therapy have Bulgaria (84,21%), Poland (78,95%), and Slovakia (78,95%). Conclusions The study revealed differences in MS patients access to DMTs, care, and services amongst included countries. Improving access to MS therapy needs an evaluation of the long-term impact of the barriers as well as frequent feedback from MS patients and stakeholders.
ER  -

SEITARIDOU, Y., M.S. PAVELIU, P. HOLKO, Dominik GREGA, I. TADIC, I STEVIC, A. MÄNNIK, T. CHAMOVA, G. PETROVA and M. KAMUSHEVA. Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis. In \textit{ISPOR Europe 2023}. 2023. ISSN~1098-3015. Available from: https://dx.doi.org/10.1016/j.jval.2023.09.1664.

Detailed Information on Publication Record